Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

SKYE Financial Statements and Analysis

PNK : SKYE

Skye Bioscience, Inc.

$1.67
-0.04-2.34%
Open: 10:14 AM

SKYE FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

SKYE Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q3Q2
revenue00000
cost of revenue00028.789K33.917K
gross profit000-28.789K-33.917K
gross profit ratio00000
research and development expenses4.883M4.079M1.946M1.255M1.788M
general and administrative expenses4.639M4.327M4.206M2.236M1.206M
selling and marketing expenses00000
selling general and administrative expenses4.639M4.327M4.206M2.236M1.206M
other expenses-4.553M-359.00021.215M209.438K
operating expenses4.969M8.406M6.152M3.491M2.995M
cost and expenses4.969M8.406M6.152M3.491M2.995M
interest income1.293M961.237K426.514K39.882K8.598K
interest expense291.068K450.052K436.936K291.814K186.429K
depreciation and amortization65.997K29.79K27.56K28.789K33.917K
ebitda-3.541M-7.415M-5.698M-3.425M-2.952M
ebitda ratio00000
operating income-3.898M-8.406M-6.152M-24.706M-2.843M
operating income ratio00000
total other income expenses net0510.826K1.135M-21.201M64.77K
income before tax-3.898M-7.895M-5.018M-24.946M-3.108M
income before tax ratio00000
income tax expense08.071K2.00K291.814K3.60K
net income-3.898M-7.903M-5.02M-24.946M-3.112M
net income ratio00000
eps-0.10-0.20-0.18-3.17-0.80
eps diluted-0.10-0.20-0.18-3.17-0.80
weighted average shs out38.819M38.669M28.00M7.881M3.886M
weighted average shs out dil38.819M38.669M28.00M7.881M3.886M
Graph

SKYE Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q3Q2
cash and cash equivalents67.413M74.121M83.343M5.126M553.443K
short term investments00000
cash and short term investments67.413M74.121M83.343M5.126M553.443K
net receivables3.678K20.00149.279K850.605K747.458K
inventory012.335M10.535M9.292M558.04K
other current assets12.396M12.884M11.078M17.314K33.746K
total current assets79.808M87.004M94.57M15.286M1.893M
property plant equipment net1.701M248.759K256.88K309.832K334.948K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets26.31K8.309K8.309K8.309K8.309K
total non current assets1.727M257.068K265.189K318.141K343.257K
other assets00000
total assets81.536M87.262M94.835M15.604M2.236M
account payables780.025K1.079M1.095M1.643M1.66M
short term debt82.932K4.939M4.685M4.236M156.067K
tax payables00000
deferred revenue01.077M2.969M1.41M1.575M
other current liabilities4.761M8.304M10.021M6.43M6.426M
total current liabilities5.624M14.323M15.801M13.719M9.817M
long term debt108.062K129.907K150.953K190.51K208.588K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities108.062K129.907K150.953K190.51K208.588K
other liabilities00000
capital lease obligations190.994K209.072K226.488K259.187K274.04K
total liabilities5.732M14.452M15.952M13.909M10.025M
preferred stock00000
common stock30.338K28.068K28.063K12.338K971.549K
retained earnings-121.203M-117.305M-109.402M-99.963M-75.017M
accumulated other comprehensive income loss00000
other total stockholders equity196.976M190.086M188.257M101.646M66.256M
total stockholders equity75.803M72.809M78.883M1.695M-7.789M
total equity75.803M72.809M78.883M1.695M-7.789M
total liabilities and stockholders equity81.536M87.262M94.835M15.604M2.236M
minority interest00000
total investments00000
total debt190.994K5.069M4.836M4.426M364.655K
net debt-67.222M-69.052M-78.507M-699.896K-188.788K
Graph

SKYE Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateSep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q3Q2
deferred income tax00021.215M1.00
stock based compensation1.922M1.828M2.478M160.207K102.871K
change in working capital2.842M-1.556M-1.286M-592.157K952.546K
accounts receivables00000
inventory00000
accounts payables-299.468K-15.64K-60.652K-90.535K331.147K
other working capital1.54M-1.54M0-501.622K621.399K
other non cash items-6.195M250.322K237.205K79.08K30.329K
net cash provided by operating activities-5.263M-7.094M-4.708M-4.055M-1.992M
investments in property plant and equipment-1.518M-32.463K-3.181K-3.673K0
acquisitions net0001.077M0
purchases of investments00000
sales maturities of investments00000
other investing activites72.837K01.145M00
net cash used for investing activites-1.446M-32.463K1.142M1.073M0
debt repayment000-73.987K-123.413K
common stock issued0-2.096M85.653M11.735M0
common stock repurchased00000
dividends paid00000
other financing activites0004.974M0
net cash used provided by financing activities0-2.096M85.653M16.635M-123.413K
effect of forex changes on cash000-13.553M0
net change in cash-6.708M-9.222M82.086M13.653M-2.115M
cash at end of period76.493M83.201M92.423M14.211M558.034K
cash at beginning of period83.201M92.423M10.337M558.034K2.673M
operating cashflow-5.263M-7.094M-4.708M-4.055M-1.992M
capital expenditure-1.518M-32.463K-3.181K-3.673K0
free cash flow-6.781M-7.126M-4.711M-4.058M-1.992M
Graph

Frequently Asked Questions

How did Skye Bioscience, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, SKYE generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Skye Bioscience, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Skye Bioscience, Inc. reported a $0.00 Gross Profit for the quarter ended Sep 30, 2024.
Have SKYE's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. SKYE incurred $4.97M worth of Operating Expenses, while it generated -$3.90M worth of Operating Income.
How much Net Income has SKYE posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Skye Bioscience, Inc., the company generated -$3.90M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Skye Bioscience, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Skye Bioscience, Inc. as of the end of the last quarter was $67.41M.
What are SKYE's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, SKYE had Total Net Receivables of $3.68K.
In terms of Total Assets and Current Assets, where did Skye Bioscience, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of SKYE were $79.81M, while the Total Assets stand at $81.54M.
As of the last quarter, how much Total Debt did Skye Bioscience, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of SKYE's debt was $190.99K at the end of the last quarter.
What were SKYE's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, SKYE reported total liabilities of $5.73M.
How much did SKYE's Working Capital change over the last quarter?
Working Capital Change for SKYE was $2.84M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
SKYE generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. SKYE generated -$5.26M of Cash from Operating Activities during its recently reported quarter.
What was SKYE's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. SKYE reported a -$6.71M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph